GLP-1s are famous for their effectiveness, infamous for their price, and remain an enigma for those deciding if and how to provide coverage of these medications for their covered populations. Omada Health is back for another webinar, where we will answer questions you've raised around risks and side effects, best practices for managing the economic impact of adoption, and the future of these drugs for the millions of individuals who may clinically qualify for them.
Join Carolyn Jasik, MD, Chief Medical Officer of Omada Health, as we return to answer these questions:
- What is the data on the short- and long-term outcomes, side effects, and risks for GLP-1s prescribed for the treatment and management of obesity?
- Are there best practices to inform who should receive these medications, and how benefits providers should approach coverage?
- GLP-1s have disrupted our approach to weight loss management. What's next?
- What is the role of evidence-based behavior modification programs for significant and sustainable weight loss in the presence of GLP-1s?
